CAMRF (Camurus AB) SpecialCharges


CAMRF Camurus AB CAMRF
83 GF Score
Price $54.00
GF Value $69.05
Valuation Modestly Undervalued
! 1 Warning Sign
View Full Analysis

What is Camurus AB SpecialCharges?

Special Charges only applies to banks.

CAMRF
83GF Score
Camurus AB CAMRF
SpecialCharges is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Camurus AB (CAMRF) Overvalued in 2026?

Based on GuruFocus' analysis, Camurus AB stock appears to be undervalued. The current stock price of $54.00 is trading 21.8% below its estimated GF Value™ of $69.05. GuruFocus considers Camurus AB to be Modestly Undervalued.

Key valuation signals for CAMRF:

  • SpecialCharges:
  • GF Value™: $69.05 vs. price of $54.00 (21.8% below fair value)
  • GF Score™: 83/100 with 1 warning sign

No single metric tells the full story. See the CAMRF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Camurus AB Business Description

Address Rydbergs torg 4, Lund, SWE, SE-224 84
Camurus AB is a science-led biopharmaceutical company focused on developing and commercializing long-acting medicines for the treatment of severe and chronic diseases. It has two approved products, including treatments for opioid dependence, and a development pipeline supported by its FluidCrystal technology. Its clinical pipeline includes product candidates for conditions such as pain, cancer, endocrine, and metabolic diseases, developed in-house and in collaboration with international pharmaceutical companies. Its pipeline programs include CAM2029 for acromegaly, gastroenteropancreatic neuroendocrine tumors, and polycystic liver disease; CAM2038 for chronic pain; CAM4072 for genetic obesity disorders; CAM2043 for Raynaud's phenomenon; CAM4071 for endocrine disorders, among others.
83GF Score

Get the complete analysis for CAMRF

SpecialCharges is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$54.00
Price
$69.05
GF Value